Pearson A S, Koch P E, Atkinson N, Xiong M, Finberg R W, Roth J A, Fang B
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
Clin Cancer Res. 1999 Dec;5(12):4208-13.
Adenoviral vectors are a widely used means of gene transfer. However, transgene expression after adenoviral administration varies among different carcinoma cell lines. We hypothesized that this variation is attributable, in part, to the presence of cell surface molecules involved in adenoviral infection. To test this, we first assessed adenovirus-mediated transgene expression in four human lung carcinoma cell lines and four human pancreatic carcinoma cell lines in terms of luciferase activities and found it to vary from 4.8 x 10(4) to 6.1 x 10(7) relative light units/microg of protein. Then, to determine whether the molecules involved in the entry of adenovirus into host cells were responsible for this variation, we evaluated the expression of alpha(v)beta5, alpha(v), beta3, alpha5, and beta1 integrins and that of coxsackievirus and adenovirus receptor (CAR) in these cell lines. Statistical analysis revealed that the levels of beta3 were associated with the levels of transgene expression. Blocking analysis showed that adenovirus-mediated gene transfer could be blocked by antibodies against these six molecules but not by the antibodies against alpha2 or alpha3 integrins, thus suggesting that the integrins alphavbeta5, alpha(v), beta3, alpha5, and beta1 and CAR molecules could limit adenovirus-mediated gene transfer when their levels fell below a certain threshold. Furthermore, cells expressing low levels of beta3 and resistant to conventional adenoviral vectors were susceptible to a vector containing the heparin-binding domain in its fiber, thus suggesting that redirecting vectors to receptors other than CAR may bypass the integrin pathway. These findings may have implications for improving the efficiency of adenovirus-mediated gene transfer and developing novel adenoviral vectors.
腺病毒载体是一种广泛应用的基因转移手段。然而,腺病毒给药后的转基因表达在不同癌细胞系中存在差异。我们推测这种差异部分归因于参与腺病毒感染的细胞表面分子的存在。为了验证这一点,我们首先根据荧光素酶活性评估了四种人肺癌细胞系和四种人胰腺癌细胞系中腺病毒介导的转基因表达,发现其相对光单位/微克蛋白质的范围为4.8×10⁴至6.1×10⁷。然后,为了确定参与腺病毒进入宿主细胞的分子是否是造成这种差异的原因,我们评估了这些细胞系中α(v)β5、α(v)、β3、α5和β1整合素以及柯萨奇病毒和腺病毒受体(CAR)的表达。统计分析表明,β3的水平与转基因表达水平相关。阻断分析表明,针对这六种分子的抗体可阻断腺病毒介导的基因转移,但针对α2或α3整合素的抗体则不能,这表明当整合素αvβ5、α(v)、β3、α5、β1和CAR分子的水平低于一定阈值时,它们可能会限制腺病毒介导的基因转移。此外,表达低水平β3且对传统腺病毒载体耐药的细胞对其纤维中含有肝素结合域的载体敏感,这表明将载体重定向至CAR以外的受体可能会绕过整合素途径。这些发现可能对提高腺病毒介导的基因转移效率和开发新型腺病毒载体具有重要意义。